Table 2.
Univariable prognostic models.
| 3-month follow-up |
12-month follow-up |
|||
|---|---|---|---|---|
| HR [95% CI] | p value | HR [95% CI] | p value | |
| Ascites MFAP4 (U/L) | 0.96 [0.93–1.00] | 0.05 | 0.96 [0.93–0.99] | 0.01 |
| Serum MFAP4 (U/L) | 1.00 [0.97–1.03] | 0.77 | 0.99 [0.97–1.01] | 0.26 |
| Child-Pugh score | 1.34 [1.01–1.78] | 0.04 | 1.29 [1.03–1.62] | 0.03 |
| MELD-Na | 1.13 [1.06–1.22] | <0.01 | 1.10 [1.04–1.17] | <0.01 |
| CLIF-C AD | 1.08 [1.03–1.14] | <0.01 | 1.06 [1.01–1.10] | 0.01 |
| Albumin (g/L) | 1.00 [0.93–1.08] | 0.93 | 1.01 [0.95–1.07] | 0.80 |
| Total ascites protein (g/L) | 0.96 [0.90–1.02] | 0.18 | 0.94 [0.89–1.00] | 0.05 |
Values in bold denote statistical significance. Univariable Cox regression of transplant-free survival. CLIF-C AD, CLIF Consortium Acute Decompensation; HR, hazard ratio; MFAP4, microfibrillar-associated protein 4; MELD-Na, model for end-stage liver disease.